The LMNA gene encodes lamins A and C with key roles in nuclear structure, signaling, chromatin organization, and genome integrity. Mutations in LMNA cause >12 diseases, termed laminopathies.
INTRODUCTION
Lamins, encoded by three human genes (LMNA, LMNB1, LMNB2), form nuclear intermediate filaments that support nuclear structure, cell mechanics, development, genome organization, DNA repair, signaling, and tissue-specific gene silencing (1) (2) (3) . Lamins have a conserved molecular structure; each polypeptide has a small globular 'head' domain, a long coiled-coil 'rod' domain, and a 'tail' comprising an Ig-fold domain as well as in the case of lamin A, an extended unstructured region (4) (5) (6) . Mutations in LMNA cause diverse tissue-specific diseases (7) . Some 'laminopathies' affect mainly striated muscle (e.g., Emery-Dreifuss muscular dystrophy; dilated cardiomyopathy) whereas others perturb metabolism, causing insulin resistance syndrome (8) or Dunnigan-type familial partial lipodystrophy (FPLD2). FPLD2 is a puberty-onset disorder characterized by lipodystrophy, muscle hypertrophy, and insulin-resistant diabetes (9, 10) , and elevated (dysregulated) hepatic glucose production (11) . LMNA missense mutations are also reported in patients with metabolic syndrome (12, 13) , although genetic causality has not been established. In rare cases, LMNA mutations cause Hutchinson-Gilford Progeria Syndrome (HGPS) or related phenotypes (14) . Most HGPS patients have a mutation that alters pre-mRNA splicing, generating a 50-residue deletion (' 50') lacking the site required for ZMPSTE24-dependent proteolytic maturation of the lamin A precursor (15, 16) . The resulting permanently-farnesylated protein, named 'progerin', has acute and long-term effects on nuclear structure and function (3, 17) .
About 35% of progerin-expressing HGPS patients are also insulin resistant (18) .
These metabolic phenotypes drew our attention to evidence that lamin A is modified by a nutrient stress-responsive enzyme named OGT (O-GlcNAc transferase), which adds a simple sugar, O-GlcNAc (β-O-linked N-acetylglucosamine), to Serine or Threonine residues of target proteins.
Endogenous lamin A is O-GlcNAc modified at two sites (S612 and T643) in mitotic HeLa cells (19) . O-GlcNAc is a ubiquitous, reversible, and dynamic modification that controls signaling, transcription, and mitosis (20) . O-GlcNAc is added to target proteins by OGT, and removed by O-GlcNAcase (OGA), each encoded by a single essential gene in mammals (21) (22) (23) . Notably, OGT is 'tuned' to metabolism in liver, kidney, and pancreatic -cells; its catalytic activity increases in tandem with cellular levels of glucose or glucosamine, which are converted via the hexosamine biosynthetic pathway to UDP-GlcNAc, the donor substrate for O-GlcNAcylation reactions (24) (25) (26) . OGT activity can protectively increase during stress, including recovery of the heart from ischemic injury (27) . However, long term cardiomyopathy associated with diabetes, aging, and hypertension all correlate with aberrantly high levels of protein O-GlcNAcylation, suggesting OGT hyper-activity perturbs heart function (28) . Protein hyper-O-GlcNAcylation has pathophysiological implications in insulin resistance, non-alcohol fatty liver disease, fibrosis, and is also characteristic of diabetic nephropathy (29) , the leading cause of chronic kidney disease and a significant long-term complication of diabetes.
We investigated potential O-GlcNAc modification of A-type lamins in hepatoma (Huh7) cells and liver tissue. We also tested recombinant purified tail domains of A-and B-type lamins as potential substrates for OGT in vitro. We report extensive O-GlcNAc modification of residues unique to lamin A in vitro, and evidence that lamin A substrate recognition by OGT requires residues deleted in HGPS. Figure   1A ). One set of samples was probed using antibody CTD 110.6 , which recognizes the O-GlcNAc modification, then stripped and reprobed for lamins A/C using antibody 5G4 ( Figure 1A ).
RESULTS

To assess potential O-GlcNAcylation of
The ~73 kD lamin A band was consistently O-
GlcNAc-positive in both concentrations of glucose (asterisk; Figure 1A Figure 1A ). These results demonstrated O-GlcNAcylation of endogenous lamin A in proliferating hepatoma cells, consistent with previous results from mitotic HeLa cells (19) .
To determine whether lamin A was O-
GlcNAcylated in a non-proliferating tissue, we analyzed liver lysates from wildtype mice that were either fasted for 24 h, or fasted 24 h and then re-fed for 12 h on a regular chow diet to boost overall protein O-GlcNAcylation (see Methods). Figure 1B ). Probing for specific proteins in the affinity-purified samples revealed enrichment for two lamin A-specific bands: the expected ~73 kD mature lamin A band and a slightly larger (~74 kD) band (sWGA; Figure 1B ). This ~74 kD band, which might represent prelamin A or a posttranslationally-modified form of mature lamin A, was not further characterized. We found similar results (sWGA purification of two presumably O-GlcNAc-modified forms of lamin A) in liver lysates from mice treated with streptozocin (STZ; Figure 1B ), which kills pancreatic -cells and models diabetes (30) . The relative abundance of the two lamin A bands could not be interpreted, because the core epitope recognized by antibody L1293 (residues 604-611; Supplemental Figure 1) adjoins a potential O-GlcNAc site (S612; (19) ) and potential phosphorylation sites (31, 32) , and may be differentially accessible on native lamin A.
O-GlcNAc
Collectively these results from hepatoma cells and mouse livers support the hypothesis that lamin A
is O-GlcNAc-modified, and hence O-GlcNAcregulated, in the liver. To explore whether OGT targets lamin A selectively, we compared the tail domains of A-and B-type lamins as biochemical substrates for OGT in vitro.
In vitro O-GlcNAcylation of recombinant lamin tails
To identify O-GlcNAc sites, we incubated recombinant lamin tail domains with purified OGT in vitro. We tested nine different tail constructs: lamin B1, lamin C, mature lamin A residues 385-646 (wildtype, S612A, T643A, or S612A/T643A), and prelamin A residues 385-664 bearing the progeria-associated Δ35, Δ50, or Δ90 deletions Figure   4B . The most frequent triple combinations were S612+S613 plus one of S616, T623, or S603; together these five sites accounted for all triples in the wildtype tail.
We also identified sites in the corresponding AspN peptide from the doublemutant (S612A/T643A; 'AA') tail, to determine how OGT responded to substrates lacking both previously identified O-GlcNAc sites (19) . The mono-GlcNAc species (invariably at S613) predominated (50.1%) over the unmodified species (24.5%; Figure 3B ). The di-and tri-GlcNAc species were also relatively abundant (18.7% and 5%), and tetra-and penta-GlcNAc species were present at <2% each ('AA'; Figure   3B ). Collectively >25% of double-mutant tails had two or more modifications ( Figure 3B ). Mass spectrometry analysis of the double mutant revealed O-GlcNAc modifications at three predominant sites (S613, S615, S616) and four less abundant sites (S618, S619, T621, T623; Figure 3B ). We were unable to site-map the mono-O-GlcNAcylated peptide corresponding to residues 639-646 due to poor sequence coverage; however, given the T643A mutation, this peptide had only one potential site, S645, suggesting O-GlcNAc-modification of residue S645 in the double-mutant. Modification at S645 was not detected in wildtype or Δ35 tails. We concluded that the S612A/T643A double-mutant tail remained attractive as a substrate for OGT.
With the S612A/T643A-mutated substrate, OGT apparently compensated by targeting three predominant sites adjoining residue 612 (S613, S615, S616) plus nearby residues S618, S619, T621, and T623. However, there were fewer 'multiples': the peptide comprising residues 596-638 was more likely to have one modification (50.1% versus 9% of wildtype), and less likely to have two (18.7% vs 35.8% of wildtype), three (5% vs 14% of wildtype), or four or more modifications (1.5% vs 3.9% of wildtype; Figure  3B ). In the peptide comprising residues 596-626, we detected di-GlcNAcylation at residues S613+S616 and S613+S615, as well as tri-GlcNAcylation at S613+S616+S618 and S613+S615+T621. In a longer version of this peptide (residues 596-638), we detected di-GlcNAcylation mainly on S613+S615 and less often on S613+(S616 or S618 or S619). Figure 5A shows the CAD spectrum of the di-GlcNAcylated species with the most abundant peaks being the charge reduced product ion with the loss of 203 and 406, one and two O-GlcNAc moieties, respectively. Figure 5B shows the ETD spectrum of the S613 and S618 di-GlcNacylated peptide with almost full sequence coverage. Tri-GlcNAcylation occurred on S613 plus different combinations of S615, S616, T621, and/or T623 as the second and third sites. We speculate that the first O-GlcNAc modification (e.g., S612 in wildtype; S613 in the AA mutant) strongly favors further modification.
The 35 tail, with nine hypothetical sites (see Figure 6 ), was modified very inefficiently: 97.7% of peptides were unmodified, with only single modifications detected at either S612 (<3% of peptide 596-664) or less frequently at S601 or S618 ( Figure 3A,B ). Peptides that included residue S613 were recovered, but unmodified, supporting the hypothesis that Δ35 greatly impairs substrate recognition or modification by OGT in vitro.
These results identify residues 601-645 as a broadly defined O-GlcNAc 'sweet spot' ( Figure   6 ), since OGT targeted this region robustly even when two abundant sites (S612 and T643) were missing ('AA' mutant; Figures 2B and 3B ). This sweet spot overlaps the region required for ZMPSTE24-dependent cleavage of prelamin A, raising the possibility that OGT might influence prelamin A maturation. However, the 'sweet spot' is also a permanent feature of mature lamin A ( Figure 7 ), suggesting OGT regulates roles unique to lamin A.
DISCUSSION
Lamin glycosylation was first suggested nearly 30 years ago (34) . The nature of this modification was unknown until O-GlcNAc sites were identified in mitotic HeLa cells (S612 and T643; (19) ) and in mouse brain (sites S611 and S613, homologous to human S612; (35) ). We found that (19, 35) . Our results independently confirm two previously-reported in vitro sites, S623 and S628 (36) . We also identified seven novel O-GlcNAc sites in mature wildtype human lamin A (S603, S613, S615, S616, S618, S619, T621) and two novel compensatory sites: S601 (identified in 35) and S645 (identified in the S612A/T643A mutant). Our results do not rule out possible O-GlcNAc sites in the neck or Ig-fold domains, since we recovered the majority of -but not all -Ser/Thr-containing peptides from these regions. However, the lack of O-GlcNAcylation of either the 50, 90, or lamin C tails strongly implies that OGT selectively targets residues 601-645 in the lamin A tail. One limitation of this study is that we did not examine the head or rod domains, or precursor residues 647-664. These regions warrant further study, since residue T91, in the coil-1B domain shared by all A-type lamins (37) , is O-GlcNAc-modified in human embryonic stem cells (38) .
Most O-GlcNAc sites in lamin A are not predicted by current algorithms
Substrate recognition by OGT is complex, involving both its TPR (protein-protein interaction) and catalytic domains, and can be influenced by post-translational modifications and partners (23, 39) . There is no strict consensus site for O-GlcNAc modification (39) . For example, a study of pre-selected 13-mer peptides showed that In agreement with Jochmann and colleagues (39), many sites on lamin A were not predicted. E.g., OGTsite (42) predicted three known sites (S612, T623, T643), and three sites we did not detect. The YinOYang O-GlcNAc prediction server (http://www.cbs.dtu.dk/services/YinOYang; 43) strongly predicted two identified sites (S612, T621), weakly predicted five identified sites (S603, S613, S615, S618, T623), failed to predict five sites (T91, S616, S619, S628, T643; 42% false negative rate) and predicted 8 other tail sites we did not detect. O-GlcNAcPRED (44) predicted only two sites (both known: S612, T643) at higher stringency; at lower stringency, this program predicted one more identified site (S601) plus three tail sites we did not detect. We suggest that O-GlcNAc sites identified in long polypeptides, rather than peptides, will be critical to improving predictive algorithms and understanding the molecular basis for OGT modifications at two or more adjoining residues, as seen for lamin A (this work) and its nuclear membrane partner, emerin (45) . 
The 'sweet spot' in relation to the site of
ZPMSTE24-dependent cleavage
Selective OGT targeting of lamin A as a mechanism for separate functions and differential regulation of lamin A vs. lamin C
The discovery that lamin A and lamin C form separate filaments is so new and unexpected (49, 50) that few studies have even attempted to distinguish one from the other. We found that OGT selectively modifies the tail domain of mature lamin A, but not lamin C, in vitro, raising the hypothesis that lamin A is uniquely and differentially regulated by OGT. These results add to growing evidence for functional specialization.
For example, lamin C specifically associates with nuclear pore complexes (50) . Specialization is also evident in the brain and in metabolism. Lamin C predominates in neurons, where mRNAs encoding (18)).
We found that progeria-associated deletions either abolished ( 50) (38) . However more work is needed to decipher mechanisms, since variants that affect metabolism, like those that cause other laminopathies, can be located throughout the polypeptide. (77) . We predict 'sweetspot' modifications are very likely to influence association with AIMP3, a scaffolding protein.
Potential impacts of O-GlcNAc on mature lamin A function
Normally found in the cytoplasm with roles in translation, AIMP3 also enters the nucleus and acts as a tumor suppressor (79) . AIMP3 binds directly to residues 641-647 in the 'sweet spot' of mature lamin A (78) . AIMP3 recruits Siah1 (an E3 ubiquitin ligase) and triggers selective degradation of mature lamin A to promote senescence (78, 79) .
Interestingly, O-GlcNAc modifications of the unstructured lamin A tail might also have a broader impact, by controlling its ability to 'fold back' and restrict access to binding sites on the Igfold domain, as suggested for actin (80) and the nuclear pore complex protein, Tpr (81) .
OGT is a master regulator that responds directly to nutrient stress, with key roles in liver, kidney and pancreatic -cells (82, 83) . Our discovery that lamin A is O-GlcNAc-modified in hepatoma cells and in liver raises the possibility, for individuals with wildtype LMNA genes, that lamin A becomes misregulated under conditions of metabolic stress, with potentially global and longterm effects on signaling, epigenetic regulation, and 3D chromatin organization (84) (85) (86) (87) . 
EXPERIMENTAL PROCEDURES
Cell culture
Peptide arrays and antibody epitope mapping
Purification of recombinant lamin tails
Recombinant His-and-T7-tagged lamin tail polypeptides were expressed in E. coli BL-21, purified using nickel NTA-agarose and stored in buffer (50 mM NaHPO 4 pH 8.0, 300 mM NaCl, 100 mM imidazole, 0.5 mM PMSF) at -80°C until use, as described (80) . 
In vitro O-GlcNAcylation reactions
Mass Spectrometry
Recombinant purified His-tagged lamin A tails symbolized by large ('major') or small ('minor') black rods, respectively. The ZPMSTE24-dependent proteolytic cleavage site is indicated. The starting points of fragments that were cleaved by ZPMSTE24 with 100%, ~50% or 0% efficiency in cells (46) are indicated below the sequence. Mutation G608S is sufficient to block cleavage in a different assay (47) . The region targeted by OGT in both wildtype and mutated lamin A tails (residues 601-645) is broadly designated the 'sweet spot', and includes 'supersweet' residues 612-623 (O-GlcNAc detected at every Ser and Thr). 
